Committee approves amendment allowing 92-day supply for injectable testosterone

Chair Rocheford, chair of the Senate Health and Human Services Committee, moved and the committee approved an amendment to House Bill 126 to allow injectable androgen prescriptions for the treatment of chronic low testosterone to be filled for up to a 92-day supply, matching current law for topically applied androgen formulations.

The amendment, identified in the hearing as 2025-3020s, removes a proposed requirement that patients ‘‘previously filled 12 prescriptions from the same medical practice for a monthly supply’’ before receiving a longer fill for injectable formulations. Chair Rocheford said that requirement was ‘‘unique to everything else in statute and law’’ and unnecessary because prescriptions for testosterone are tracked in the prescription drug monitoring program, which can reveal potential doctor-shopping.

The committee discussed practical aspects of typical injectable dosing. Chair Rocheford noted that ‘‘these are prescriptions that are delivered at a 1 milliliter dose once a week, and the bottles that they come in, that standard bottles are 10 bottles,’’ and said the manufacturers’ packaging supports a 92-day supply.

There was no recorded opposition in the committee when members voted to pass the amendment and then to move the bill as amended; the vote was taken by voice and recorded as consent. The committee moved House Bill 126 forward as amended.

The amendment aligns dispensing rules for injectable androgen with existing rules for topical androgen products and leaves intact the requirement that prescribers indicate the medication is for treatment of chronic low testosterone as specified in the bill text.

The committee proceeded to the next agenda items after the vote.